

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Mantle Cell, Diffuse Large B-Cell and Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. In the ongoing Phase I/II BRUIN trial for patients with mantle cell lymphoma, which BTK (Bruton tyrosine kinase) inhibitor has demonstrated promising activity for previously treated disease?**

 - Acalabrutinib
 - Duvelisib
 - LOXO-305**
 - Venetoclax
 - Zanubrutinib
- 2. Which of the following statements is FALSE regarding tafasitamab for patients with diffuse large B-cell lymphoma?**

 - It is an antibody targeting CD19
 - It is well tolerated in combination with lenalidomide
 - It negatively affects CD19-directed CAR T-cell therapy in vitro**
- 3. The Phase III ECHELON-1 trial comparing brentuximab vedotin (BV) with doxorubicin/vinblastine/dacarbazine (AVD) to bleomycin with AVD for patients with previously untreated Stage III or IV classical Hodgkin lymphoma demonstrated which of the following progression-free survival outcomes at 5 years of follow-up?**

 - No significant improvement with BV/AVD
 - Significant improvement with BV/AVD**
- 4. Which of the following drug types best describes polatuzumab vedotin?**

 - Antibody-drug conjugate**
 - Immune checkpoint inhibitor
 - CAR T-cell therapy